Drugs / DTaP IPV HB PRP~T vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00831753 | May 2008 → May 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00404651 | Nov 2006 → Apr 2008 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP IPV HB PRP~T vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00831753 ↗ |
| Modality | Vaccine | “Biological: DTaP-IPV-HB-PRP~T vaccine” NCT00404651 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular (IM)” NCT00404651 ↗ |